Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk ...

Narcolepsy can be described as a neurological condition that has chronic consequences on the regulation of the sleep-wake ...

Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.

The latest announcement is out from Alkermes ( (ALKS) ).

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

St. Luke’s University Health Network opens a $1.8M expanded Sleep Lab at its Miners Campus, boosting access to sleep disorder ...

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), ...

The scope of all human knowledge is, understandably, so massive that no one person can manage to fully comprehend even a ...

Lucid Group, Inc. , maker of the world's most advanced electric vehicles, today announced that the Lucid Gravity SUV has been recognized by the MotorTrend Best Tech Awards for delivering the Best ...

ADHD medications work like sleep, not attention boosters, massive brain study reveals. For some kids, focus problems may be ...

The precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035[1], driven by a fundamental shift in cancer treatment philosophy. Biomarker-guided therapy ...

Her family brought her to the hospital, but they sent her home a month later, with a diagnosis that made no sense at all.